Saturday 25 February 2012
KRAS-associated cancer; KRAS-driven oncogenesis; Cancer Harboring KRAS Mutations; Kras-driven tumor development; oncogenic KRAS-driven cancers; RAS mutant tumors
More than a third of all human cancers, including a high percentage of pancreatic, lung, and colorectal cancers, are driven by mutations and possibly amplification (increased copies) of RAS genes.
- KRAS-driven pancreatic adenocarcinoma (95%)
- KRAS-driven colorectal adenocarcinoma (45%)
- KRAS-driven pulmonary adenocarcinoma (35%)
- NRAS-driven AML (30%)
- NRAS-driven melanoma (15%)
- HRAS-driven bladder cancer (15%)
KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. (23887294)
- Developing ways to block RAS gene function has been a challenge.
- NCI launched the RAS Program due to the magnitude of this challenge, as well as the potential clinical benefit.
- The RAS gene family—which includes KRAS, HRAS, and NRAS—encodes for proteins involved in cell signaling.
- When RAS genes are mutated, cells grow uncontrollably and evade signals to die. RAS mutations can also allow cells to resist available cancer therapies.
KRAS (Ki-ras, Kras)